INTERNATIONAL BIOTECHNOLOGY TRUST PLC
Reported holdings as of Q3 2023, from 20 quarterly filings.
This filer last reported in Q3 2023; the most recent quarter on file across all filers is Q2 2026. Firms that restructure stop filing under one CIK and start under another, so a successor entity may hold these positions now under a similar name.
Holdings
| Security | Ticker | Value | Shares | Weight | Weight change | Held | Change |
|---|---|---|---|---|---|---|---|
| AMGEN INC | AMGN | $21.3M | 79,246 | -0.75pp | 20q | -32.4%-$10.2M | |
| INCYTE CORP | INCY | $20.7M | 358,454 | +0.19pp | 20q | HELD | |
| GILEAD SCIENCES INC | GILD | $17.5M | 233,584 | +2.51pp | 20q | +61.6%+$6.7M | |
| INTRA-CELLULAR THERAPIES INC | ITCI | $16.5M | 317,856 | +2.17pp | 15q | +79.7%+$7.3M | |
| BIOMARIN PHARMACEUTICAL INC | BMRN | $13.6M | 153,656 | +3.03pp | 20q | +162.0%+$8.4M | |
| SUPERNUS PHARMACEUTICALS | SUPN | $11.8M | 426,500 | -0.83pp | 10q | -18.5%-$2.7M | |
| VERA THERAPEUTICS INC | VERA | $10.4M | 758,355 | -1.26pp | 8q | -22.2%-$3.0M | |
| BIOGEN INC | BIIB | $10.3M | 40,200 | +2.53pp | 6q | +265.5%+$7.5M | |
| HARMONY BIOSCIENCES HLDGS IN | HRMY | $10.3M | 314,500 | -2.64pp | 10q | -44.9%-$8.4M | |
| MIRATI THERAPEUTICS INC | MRTX | $9.4M | 216,000 | +0.31pp | 19q | -16.9%-$1.9M | |
| ULTRAGENYX PHARMACEUTICAL IN | RARE | $8.9M | 250,052 | +1.88pp | 11q | +212.4%+$6.1M | |
| UNIQURE NV | QURE | $8.3M | 1,241,500 | +2.75pp | 18q | +7909.7%+$8.2M | |
| AURINIA PHARMACEUTICALS INC | AUPH | $8.1M | 1,040,530 | +1.03pp | 13q | +81.4%+$3.6M | |
| UNITED THERAPEUTICS CORP DEL | UTHR | $7.7M | 33,959 | -0.97pp | 7q | -35.6%-$4.2M | |
| VERTEX PHARMACEUTICALS INC | VRTX | $7.3M | 21,000 | +0.21pp | 3q | HELD | |
| REGENERON PHARMACEUTICALS | REGN | $7.3M | 8,847 | -3.45pp | 14q | -67.2%-$14.9M | |
| ILLUMINA INC | ILMN | $6.9M | 50,500 | -0.55pp | 9q | HELD | |
| ALNYLAM PHARMACEUTICALS INC | ALNY | $6.5M | 36,800 | -2.52pp | 20q | -54.9%-$7.9M | |
| AMYLYX PHARMACEUTICALS INC | AMLX | $5.4M | 295,000 | +1.65pp | 2q | +1080.0%+$4.9M | |
| KRYSTAL BIOTECH INC | KRYS | $5.3M | 46,092 | +0.16pp | 8q | HELD | |
| KARUNA THERAPEUTICS INC | KRTX | $5.2M | 30,500 | +0.04pp | 3q | +18.7%+$811.6K | |
| AXSOME THERAPEUTICS INC | AXSM | $4.1M | 58,300 | +0.10pp | 2q | HELD | |
| ERASCA INC | ERAS | $3.8M | 1,926,000 | +0.08pp | 3q | +35.1%+$985.0K | |
| ACADIA PHARMACEUTICALS INC | ACAD | $3.7M | 179,702 | +0.16pp | 4q | +19.0%+$597.3K | |
| REVANCE THERAPEUTICS INC | RVNC | $3.3M | 288,726 | -1.11pp | 5q | HELD | |
| NEUROCRINE BIOSCIENCES INC | NBIX | $3.2M | 28,877 | -0.88pp | 2q | -58.1%-$4.5M | |
| SAREPTA THERAPEUTICS INC | SRPT | $3.2M | 26,700 | +0.43pp | 2q | +42.0%+$957.2K | |
| ROCKET PHARMACEUTICALS INC | RCKT | $3.2M | 156,000 | +0.13pp | 9q | HELD | |
| DENALI THERAPEUTICS INC | DNLI | $3.2M | 154,000 | -0.62pp | 8q | -18.1%-$700.4K | |
| ASTRAZENECA PLC | AZN | $3.1M | 46,500 | - | new | NEW | |
| XENON PHARMACEUTICALS INC | XENE | $3.1M | 91,500 | +0.75pp | 10q | +258.8%+$2.3M | |
| CRISPR THERAPEUTICS AG | CRSP | $2.9M | 63,000 | - | new | NEW | |
| MADRIGAL PHARMACEUTICALS INC | MDGL | $2.7M | 18,300 | -0.39pp | 2q | HELD | |
| LEGEND BIOTECH CORP | LEGN | $2.6M | 38,000 | +0.06pp | 9q | HELD | |
| HALOZYME THERAPEUTICS INC | HALO | $2.4M | 62,200 | -0.25pp | 3q | -34.9%-$1.3M | |
| MARINUS PHARMACEUTICALS INC | MRNS | $2.3M | 290,000 | +0.49pp | 2q | +222.2%+$1.6M | |
| BEONE MEDICINES LTD | ONC | $2.3M | 12,700 | +0.30pp | 8q | +46.0%+$718.6K | |
| JAZZ PHARMACEUTICALS PLC | JAZZ | $2.2M | 17,200 | +0.10pp | 10q | HELD | |
| MIRUM PHARMACEUTICALS INC | MIRM | $2.1M | 67,500 | +0.19pp | 5q | HELD | |
| IOVANCE BIOTHERAPEUTICS INC | IOVA | $2.0M | 445,000 | +0.54pp | 13q | +584.6%+$1.7M | |
| IONIS PHARMACEUTICALS INC | IONS | $1.9M | 43,000 | +0.12pp | 3q | HELD | |
| ZAI LAB LTD | ZLAB | $1.9M | 78,958 | -0.02pp | 10q | HELD | |
| GENMAB A/S | GMAB | $1.6M | 44,300 | - | new | NEW | |
| CELLDEX THERAPEUTICS INC NEW | CLDX | $1.3M | 48,099 | -0.05pp | 2q | HELD | |
| COGENT BIOSCIENCES INC | COGT | $1.3M | 135,000 | - | new | NEW | |
| DYNE THERAPEUTICS INC | DYN | $1.2M | 137,751 | -0.62pp | 11q | -54.2%-$1.5M | |
| NOVOCURE LTD | NVCR | $1.2M | 74,000 | flat | 6q | +131.2%+$677.5K | |
| AMICUS THERAPEUTICS INC | FOLD | $1.1M | 90,000 | - | new | NEW | |
| CYTOKINETICS INC | CYTK | $1.1M | 37,000 | flat | 2q | HELD | |
| GUARDANT HEALTH INC | GH | $1.1M | 36,500 | -0.03pp | 10q | HELD | |
| INSMED INC | INSM | $1.0M | 40,100 | +0.08pp | 19q | HELD | |
| BLUEPRINT MEDICINES CORP | BPMC | $1.0M | 20,000 | - | new | NEW | |
| AKERO THERAPEUTICS INC | AKRO | $935.2K | 18,489 | -0.80pp | 2q | -76.4%-$3.0M | |
| KEZAR LIFE SCIENCES INC | KZR | $830.5K | 703,825 | - | new | NEW | |
| INTELLIA THERAPEUTICS INC | NTLA | $757.9K | 24,000 | -0.04pp | 8q | HELD | |
| PROTHENA CORP PLC | PRTA | $722.9K | 15,000 | - | new | NEW | |
| AGIOS PHARMACEUTICALS INC | AGIO | $593.5K | 24,000 | -0.01pp | 2q | HELD | |
| BEAM THERAPEUTICS INC | BEAM | $564.7K | 23,500 | -0.04pp | 6q | HELD | |
| VENTYX BIOSCIENCES INC | VTYX | $520.6K | 15,000 | +0.03pp | 3q | HELD | |
| VIR BIOTECHNOLOGY INC | VIR | $439.9K | 47,000 | - | new | NEW | |
| NOVABRIDGE BIOSCIENCES | NBP | $409.9K | 310,499 | -0.14pp | 11q | HELD | |
| PTC THERAPEUTICS INC | PTCT | $380.6K | 17,000 | -0.08pp | 19q | HELD | |
| ARVINAS INC | ARVN | $333.5K | 17,000 | -0.02pp | 5q | HELD | |
| PROTAGONIST THERAPEUTICS INC | PTGX | $331.9K | 19,900 | -0.06pp | 2q | HELD | |
| RELMADA THERAPEUTICS INC | RLMD | $30.0K | 10,000 | flat | 9q | HELD |
By sector
Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.
| Sector | Value | Share |
|---|---|---|
| Biotech & Pharma | $253.4M | 85.4% |
| Other sectors | $2.3M | 0.8% |
| Not classified | $41.1M | 13.9% |
Quarter by quarter
| Quarter | Value | Positions | New | Added | Trimmed | Exited | Top 10 | Days to file |
|---|---|---|---|---|---|---|---|---|
| Q3 2023 | $296.8M | 65 | 9 | 17 | 13 | 5 | 47.8% | 45 |
| Q2 2023 | $328.5M | 61 | 13 | 17 | 12 | 16 | 51.5% | 39 |
| Q1 2023 | $358.4M | 64 | 7 | 17 | 7 | 6 | 49.9% | 48 |
| Q4 2022 | $323.8M | 63 | 3 | 9 | 7 | 6 | 51.2% | 32 |
| Q3 2022 | $311.9M | 66 | 6 | 59 | 1 | 18 | 48.3% | 39 |
| Q2 2022 | $9.6M | 78 | 15 | 1 | 62 | 7 | 47.0% | 47 |
| Q1 2022 | $443.4M | 70 | 8 | 12 | 20 | 11 | 47.3% | 50 |
| Q4 2021 | $448.9M | 73 | 13 | 18 | 10 | 8 | 46.7% | 46 |
| Q3 2021 | $414.6M | 68 | 10 | 22 | 9 | 8 | 52.3% | 43 |
| Q2 2021 | $378.8M | 66 | 15 | 14 | 7 | 5 | 54.1% | 42 |
| Q1 2021 | $378.1M | 56 | 9 | 14 | 9 | 5 | 55.2% | 47 |
| Q4 2020 | $366.1M | 52 | 5 | 13 | 4 | 6 | 57.0% | 50 |
| Q3 2020 | $309.8M | 53 | 5 | 12 | 7 | 5 | 58.2% | 62 |
| Q2 2020 | $300.8M | 53 | 3 | 11 | 10 | 6 | 57.0% | 14 |
| Q1 2020 | $219.4M | 56 | 8 | 7 | 20 | 15 | 60.7% | 48 |
| Q4 2019 | $277.6M | 63 | 9 | 19 | 11 | 4 | 51.2% | 139 |
| Q3 2019 | $216.4M | 58 | 2 | 13 | 15 | 8 | 56.7% | 45 |
| Q2 2019 | $269.7M | 64 | 9 | 19 | 15 | 7 | 48.6% | 45 |
| Q1 2019 | $270.7M | 62 | 21 | 14 | 12 | 4 | 43.7% | 44 |
| Q4 2018 | $161.1M | 45 | 0 | 0 | 0 | 0 | 56.9% | 45 |
Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.
Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.
Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.